IHIVARNA

Therapeutic TriMix / mRNA based Vaccine in Chronic HIV-1 Infected Patients Receiving Antiretroviral Therapy

Coordinatore	CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER    more  Organization address address: CALLE ROSSELLO 149 PUERTA BJS city: BARCELONA postcode: 8036 contact info Titolo: Dr. Nome: Pastora Cognome: Martinez Samper Email: send email Telefono: +34 93 227 5707 Fax: +34 93 227 9205
Nazionalità Coordinatore	Spain [ES]
Totale costo	7˙826˙907 €
EC contributo	5˙984˙720 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-12-01   -   2017-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER  Organization address address: CALLE ROSSELLO 149 PUERTA BJS city: BARCELONA postcode: 8036 contact info Titolo: Dr. Nome: Pastora Cognome: Martinez Samper Email: send email Telefono: +34 93 227 5707 Fax: +34 93 227 9205	ES (BARCELONA)	coordinator	1˙133˙720.00
2	ETHERNA BVBA  Organization address address: ARTHUR DE CONINCKSTRAAT 11 city: KORTENBERG postcode: 3070 contact info Titolo: Mrs. Nome: Hilde Cognome: Van Raemdonck Email: send email Telefono: +32 486534516 Fax: +32 24774568	BE (KORTENBERG)	participant	1˙718˙520.00
3	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM  Organization address address: 's Gravendijkwal 230 city: ROTTERDAM postcode: 3015CE contact info Titolo: Mr. Nome: Wim Cognome: Leep Email: send email Telefono: +31 107044066	NL (ROTTERDAM)	participant	854˙800.00
4	PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE  Organization address address: Nationalestraat 155 city: ANTWERPEN postcode: 2000 contact info Titolo: Ms. Nome: Nadine Cognome: Van Peer Email: send email Telefono: +32 32476202 Fax: +32 32476333	BE (ANTWERPEN)	participant	818˙060.00
5	FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA  Organization address address: CARRETERA DE CANYET city: BARCELONA postcode: 8916 contact info Titolo: Ms. Nome: Lourdes Cognome: Grau Email: send email Telefono: +34 934656374 Fax: +34 934653968	ES (BARCELONA)	participant	667˙700.00
6	VRIJE UNIVERSITEIT BRUSSEL  Organization address address: PLEINLAAN 2 city: BRUSSEL postcode: 1050 contact info Titolo: Prof. Nome: Nik Cognome: Claesen Email: send email Telefono: 3226292210 Fax: 3226293640	BE (BRUSSEL)	participant	322˙720.00
7	SYNAPSE RESEARCH MANAGEMENT PARTNERS SL  Organization address address: CALLE LLACUNA 162 city: BARCELONA postcode: 8018 contact info Titolo: Ms. Nome: Sandra Cognome: Pla Email: send email Telefono: +34 933006061	ES (BARCELONA)	participant	308˙800.00
8	ASPHALION SL  Organization address address: VIA AUGUSTA 59 PLANTA 1 DESPACHO city: BARCELONA postcode: 8006 contact info Titolo: Mrs. Nome: Montse Cognome: Perez Email: send email Telefono: +34 932385945 Fax: 34932385946	ES (BARCELONA)	participant	160˙400.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'To find a therapy alternative to cART for life is one of the hot topics of investigation in HIV field. Therapeutic vaccination seems to be the best option. We have reported in a double-blind placebo controlled study some of the best, most solid data showing that HIV-1 specific immune responses elicited by therapeutic dendritic cell (DC) vaccines pulsed ex vivo with inactivated autologous whole virus could significantly change pVL set-point (mean peak drop of -1.2 log10 copies/ml). Similar efficacy has been found in a preliminary non controlled clinical trial using DC electroporated with mRNA encoding autologous HIV-1 antigens. However, the logistics of developing a specific vaccine by ex vivo manipulating autologous DC for each patient may be prohibitive. Therefore, we propose that in vivo targeting of DC by direct administration of a rational designed HIV mRNA encoding immunomodulating proteins might be an attractive alternative to target DCs in situ. Our candidate is highly innovative: 1. It is a mRNA based immunogen: it is expected to have a good safety profile, it is classified as nongene therapy by the American and German authorities, is easier to produce and to store regardless of the encoded antigen and is not restricted to a defined HLA type of individuals. 2. The HIV antigen encoded by mRNA has been selected with a rational design: based on our previous works selecting viral targets of protective HIV-1 specific T cell responses in 3 large cohorts of HIV infected individuals. 3. The candidate includes TriMix to target DC in vivo: our data suggest that mRNA encoding a mixture of antigen presenting cells activation molecules (CD40L, a constitutive active variant of TLR4 and CD70) significantly enhanced the induction of antigen-specific T cells. If this candidate would be able to obtain the functional cure in at least a proportion of patients it could be applicable to developing countries and would improve the care and cost of HIV infection.'